Humacyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $1.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors highlighted during Humacyte’s recent KOL call, which underscored ATEV’s potential to address unmet needs in arteriovenous access for hemodialysis. He views the favorable expert feedback on ATEV’s clinical and economic benefits, along with the encouraging female subgroup data from the V007 Phase III study, as reinforcing the long-term value of the platform beyond its current trauma indication.
Jennings also points to the large end-stage renal disease market and the ongoing V012 Phase III trial in female hemodialysis patients, with interim data expected in 2Q26, as key upside drivers. While recognizing that Symvess’s extremity vascular trauma use is the primary near-term growth engine, he believes the broader hemodialysis opportunity provides significant expansion potential, supporting his Buy rating and unchanged $1 price target.
According to TipRanks, Jennings is a 3-star analyst with an average return of 0.9% and a 44.09% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Abbott Laboratories.